Phaseline

Targets › BLM

BLM (RecQ-like DNA helicase BLM): drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 2; Other; next expected readout Dec 2026.

ATP-dependent DNA helicase that unwinds double-stranded (ds)DNA in a 3'-5' direction. Participates in DNA replication and repair. (UniProt, P54132)

Open in Phaseline: the race on BLM, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
West China HospitalBleomycin
DNA-damaging antibiotic with sclerosing properties
BLMPhase 2Lymphatic MalformationDec 2026

Conditions

Lymphatic Malformation (1)

Modalities

small molecule (1)

Companies

West China Hospital (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.